Categories: News

LENSAR to Present at the Oppenheimer MedTech, Tools, & Diagnostics Summit

ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the Oppenheimer MedTech, Tools, & Diagnostics Summit on May 26, 2021.

Mr. Curtis’ presentation will be available on-demand beginning at 8:00 a.m. Eastern Time on May 26, 2021 and can be accessed through the Investors section of the Company’s website at https://ir.lensar.com. The webcast will be available for two weeks after the presentation has been posted.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision.

Contacts

Thomas R. Staab, II, CFO

ir.contact@lensar.com

Lee Roth / Cameron Radinovic

Burns McClellan for LENSAR

lroth@burnsmc.com / cradinovic@burnsmc.com

Staff

Recent Posts

Cosmo’s Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China

Dublin, Ireland--(Newsfile Corp. - June 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43)…

2 hours ago

Healing Realty Trust Closes First Tranche of Series A to Expand Clinic-Focused Portfolio for a New Generation of Medicine

Investment to fund acquisitions of three operating healthcare facilities in Texas, Ohio and Connecticut, totaling…

3 hours ago

RayStation Used for First-Ever Radiotherapy Treatment with Hitachi’s OXRAY system

STOCKHOLM, June 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce a…

3 hours ago

Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers

STOCKHOLM, June 18, 2024 /PRNewswire/ -- Oblique Therapeutics, a leading biotechnology company specialising in the development…

3 hours ago

Single-Cell Functional Profiling Using Nanovial Technology Unveils the Therapeutic Potential of Extracellular Vesicles

LOS ANGELES, June 18, 2024 /PRNewswire/ -- Partillion Bioscience Corporation ("Partillion"), a life science tools…

3 hours ago